Theralase Technologies Inc. (CVE:TLT – Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as C$2.18 and last traded at C$0.21, with a volume of 49500 shares trading hands. The stock had previously closed at C$0.20.
Theralase Technologies Stock Up 7.7%
The firm has a 50 day moving average price of C$0.19 and a 200-day moving average price of C$0.23. The company has a debt-to-equity ratio of 14.85, a current ratio of 1.91 and a quick ratio of 3.40. The firm has a market cap of C$51.14 million, a price-to-earnings ratio of -11.19 and a beta of 1.36.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
See Also
- Five stocks we like better than Theralase Technologies
- How Investors Can Find the Best Cheap Dividend Stocks
- D-Wave Goes International With South Korea Partnership
- Most active stocks: Dollar volume vs share volume
- Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
- Stock Splits, Do They Really Impact Investors?
- 5 Small Cap Stocks With Explosive Upside Potential
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
